These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

414 related articles for article (PubMed ID: 17547501)

  • 21. Viral response in stable patients switching to fosamprenavir/ritonavir monotherapy (the FONT Study).
    Saumoy M; Tiraboschi J; Gutierrez M; Niubó J; Domingo P; Vila A; Podzamczer D
    HIV Med; 2011 Aug; 12(7):438-41. PubMed ID: 21729229
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Efficacy of atazanavir in treatment-naive patients].
    Moreno S; Hernández B; Dronda F
    Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 17():9-13. PubMed ID: 20116611
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics of Telzir (fosamprenavir).
    Wilkins E
    J HIV Ther; 2004 Nov; 9(4):87-91. PubMed ID: 15731740
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Drug resistance genotypes predict response to amprenavir-containing regimens in highly drug-experienced HIV-1-infected patients.
    Sabin CA; Wilkins E; Murphy M; Fisher M; de Ruiter A; Easterbrook PJ; Leen C; Vlahakis E; Cane PA; Li X; Pillay D;
    Antivir Ther; 2003 Aug; 8(4):301-8. PubMed ID: 14518699
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Selection of resistance in protease inhibitor-experienced, human immunodeficiency virus type 1-infected subjects failing lopinavir- and ritonavir-based therapy: mutation patterns and baseline correlates.
    Mo H; King MS; King K; Molla A; Brun S; Kempf DJ
    J Virol; 2005 Mar; 79(6):3329-38. PubMed ID: 15731227
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Are all boosted protease inhibitors the same? Previously treated patients profit too from lopinavir/r].
    MMW Fortschr Med; 2003 Dec; 145(50):61. PubMed ID: 14963981
    [No Abstract]   [Full Text] [Related]  

  • 27. Efficacy and tolerability of a double boosted protease inhibitor (lopinavir + saquinavir/ritonavir) regimen in HIV-infected patients who failed treatment with nonnucleoside reverse transcriptase inhibitors.
    Chetchotisakd P; Anunnatsiri S; Mootsikapun P; Kiertiburanakul S; Anekthananon T; Bowonwatanuwong C; Kowadisaiburana B; Supparatpinyo K; Ruxrungtham K;
    HIV Med; 2007 Nov; 8(8):529-35. PubMed ID: 17944686
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients.
    Delfraissy JF; Flandre P; Delaugerre C; Ghosn J; Horban A; Girard PM; Norton M; Rouzioux C; Taburet AM; Cohen-Codar I; Van PN; Chauvin JP
    AIDS; 2008 Jan; 22(3):385-93. PubMed ID: 18195565
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics of concurrent administration of fosamprenavir and atazanavir without ritonavir in human immunodeficiency virus-negative subjects.
    McRae M; Clay PG; Anderson PL; Glaros AG
    Pharmacotherapy; 2009 Aug; 29(8):937-42. PubMed ID: 19637947
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mutational patterns and correlated amino acid substitutions in the HIV-1 protease after virological failure to nelfinavir- and lopinavir/ritonavir-based treatments.
    Garriga C; Pérez-Elías MJ; Delgado R; Ruiz L; Nájera R; Pumarola T; Alonso-Socas Mdel M; García-Bujalance S; Menéndez-Arias L;
    J Med Virol; 2007 Nov; 79(11):1617-28. PubMed ID: 17854027
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-HIV agents. Saquinavir with fosamprenavir.
    TreatmentUpdate; 2004; 16(3):9. PubMed ID: 17219609
    [No Abstract]   [Full Text] [Related]  

  • 32. Lopinavir/ritonavir: a review of its use in the management of HIV infection.
    Cvetkovic RS; Goa KL
    Drugs; 2003; 63(8):769-802. PubMed ID: 12662125
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Individualized therapy with fosamprenavir/r. A PI suitable in liver problems].
    MMW Fortschr Med; 2008 Apr; 150 Spec No 1():60-1. PubMed ID: 19031566
    [No Abstract]   [Full Text] [Related]  

  • 34. Lopinavir plus ritonavir: a novel protease inhibitor combination for HIV infections.
    Tan D; Walmsley S
    Expert Rev Anti Infect Ther; 2007 Feb; 5(1):13-28. PubMed ID: 17266450
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preliminary safety and efficacy data of brecanavir, a novel HIV-1 protease inhibitor: 24 week data from study HPR10006.
    Lalezari JP; Ward DJ; Tomkins SA; Garges HP
    J Antimicrob Chemother; 2007 Jul; 60(1):170-4. PubMed ID: 17491001
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fosamprenavir: a review of its use in the management of antiretroviral therapy-naive patients with HIV infection.
    Chapman TM; Plosker GL; Perry CM
    Drugs; 2004; 64(18):2101-24. PubMed ID: 15341507
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Drug interactions. Amprenavir with low-dose ritonavir.
    TreatmentUpdate; 2006; 18(3):9-10. PubMed ID: 17211921
    [No Abstract]   [Full Text] [Related]  

  • 38. Fosamprenavir : clinical pharmacokinetics and drug interactions of the amprenavir prodrug.
    Wire MB; Shelton MJ; Studenberg S
    Clin Pharmacokinet; 2006; 45(2):137-68. PubMed ID: 16485915
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Unboosted fosamprenavir is associated with low drug exposure in HIV-infected patients with mild-moderate liver impairment resulting from HCV-related cirrhosis.
    Gatti F; Nasta P; Loregian A; Puoti M; Matti A; Pagni S; de Requena DG; Prestini K; Parisi SG; Bonora S; Palù G; Carosi G
    J Antimicrob Chemother; 2009 Mar; 63(3):575-8. PubMed ID: 19151039
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Plasma amprenavir pharmacokinetics and tolerability following administration of 1,400 milligrams of fosamprenavir once daily in combination with either 100 or 200 milligrams of ritonavir in healthy volunteers.
    Ruane PJ; Luber AD; Wire MB; Lou Y; Shelton MJ; Lancaster CT; Pappa KA;
    Antimicrob Agents Chemother; 2007 Feb; 51(2):560-5. PubMed ID: 17088488
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.